Prognostic significance of baseline thyroid variables in IDH-wildtype glioblastoma patients treated with regorafenib

被引：0
|
作者：
McLean, Aaron Lawson [1 ]
机构：
[1] Friedrich Schiller Univ Jena, Jena Univ Hosp, Dept Neurosurg, Klinikum 1, D-07747 Jena, Germany
来源：
JOURNAL OF NEURO-ONCOLOGY | 2023年 / 164卷 / 1期
关键词：
Thyroid function; Regorafenib; Glioblastoma; IDH Mutation; Treatment response; Multicenter Study;
D O I：
10.1007/s11060-023-04408-1
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：267 / 268
页数：2
相关论文
共 50 条
  • [1] Prognostic significance of baseline thyroid variables in IDH-wildtype glioblastoma patients treated with regorafenib
    Aaron Lawson McLean
    [J]. Journal of Neuro-Oncology, 2023, 164 : 267 - 268
  • [2] PROGNOSTIC IMPACT OF TUMOR MUTATIONAL BURDEN AT BASELINE IN IDH-WILDTYPE GLIOBLASTOMA
    Park, Dohoon
    Park, Hwan
    Kim, Yongjae
    Park, Kang-Seo
    Park, Ji Eun
    Sung, Chang Ohk
    Yoon, Shinkyo
    Lee, Ho-Su
    [J]. NEURO-ONCOLOGY, 2023, 25
  • [3] THE PROGNOSTIC AND PREDICTIVE SIGNIFICANCE OF PARTIAL MGMT PROMOTER METHYLATION FOR IDH-WILDTYPE GLIOBLASTOMA PATIENTS
    Torre, Matthew
    Iorgulescu, Bryan
    [J]. NEURO-ONCOLOGY, 2022, 24 : 10 - 10
  • [4] Updates in IDH-Wildtype Glioblastoma
    Melhem, Jawad M.
    Detsky, Jay
    Lim-Fat, Mary Jane
    Perry, James R.
    [J]. NEUROTHERAPEUTICS, 2022, 19 (06) : 1705 - 1723
  • [5] Updates in IDH-Wildtype Glioblastoma
    Jawad M. Melhem
    Jay Detsky
    Mary Jane Lim-Fat
    James R. Perry
    [J]. Neurotherapeutics, 2022, 19 : 1705 - 1723
  • [6] Prognostic importance of temozolomide-induced neutropenia in glioblastoma, IDH-wildtype patients
    Taiichi Saito
    Kazuhiko Sugiyama
    Seiji Hama
    Fumiyuki Yamasaki
    Takeshi Takayasu
    Ryo Nosaka
    Yoshihiro Muragaki
    Takakazu Kawamata
    Kaoru Kurisu
    [J]. Neurosurgical Review, 2018, 41 : 621 - 628
  • [7] Prognostic importance of temozolomide-induced neutropenia in glioblastoma, IDH-wildtype patients
    Saito, Taiichi
    Sugiyama, Kazuhiko
    Hama, Seiji
    Yamasaki, Fumiyuki
    Takayasu, Takeshi
    Nosaka, Ryo
    Muragaki, Yoshihiro
    Kawamata, Takakazu
    Kurisu, Kaoru
    [J]. NEUROSURGICAL REVIEW, 2018, 41 (02) : 621 - 628
  • [8] Impact of frailty on survival glioblastoma, IDH-wildtype patients
    Hudelist, Benoit
    Elia, Angela
    Roux, Alexandre
    Paun, Luca
    Schumacher, Xavier
    Hamza, Meissa
    Demasi, Marco
    Moiraghi, Alessandro
    Dezamis, Edouard
    Chretien, Fabrice
    Benzakoun, Joseph
    Oppenheim, Catherine
    Zanello, Marc
    Pallud, Johan
    [J]. JOURNAL OF NEURO-ONCOLOGY, 2024, 169 (01) : 61 - 72
  • [9] Distribution and favorable prognostic implication of genomic EGFR alterations in IDH-wildtype glioblastoma
    Higa, Nayuta
    Akahane, Toshiaki
    Hamada, Taiji
    Yonezawa, Hajime
    Uchida, Hiroyuki
    Makino, Ryutaro
    Watanabe, Shoji
    Takajo, Tomoko
    Yokoyama, Seiya
    Kirishima, Mari
    Matsuo, Kei
    Fujio, Shingo
    Hanaya, Ryosuke
    Tanimoto, Akihide
    Yoshimoto, Koji
    [J]. CANCER MEDICINE, 2023, 12 (01): : 49 - 60
  • [10] Prognostic significance of MRI contrast enhancement in newly diagnosed glioblastoma, IDH-wildtype according to WHO 2021 classification
    Roux, Alexandre
    Elia, Angela
    Hudelist, Benoit
    Benzakoun, Joseph
    Dezamis, Edouard
    Parraga, Eduardo
    Moiraghi, Alessandro
    Simboli, Giorgia Antonia
    Chretien, Fabrice
    Oppenheim, Catherine
    Zanello, Marc
    Pallud, Johan
    [J]. JOURNAL OF NEURO-ONCOLOGY, 2024, 169 (02) : 445 - 455
12345